Companies › Direct Biologics
2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 3; Respiratory, Immunology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ExoFlo Bone marrow mesenchymal stem cell derived extracellular vesicles | – | Phase 3 | Acute Respiratory Distress Syndrome | Nov 2027 |
| DB-3Q Acellular secretome proteins and extracellular vesicles from bone marrow-derived mesenchym | – | Phase 2 | Crohn Disease (CD); Perianal Fistula Due to Crohn's Disease | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07625293 | DB-3Q | Phase 2 | Crohn Disease (CD) | Immunology | Jun 2027 |
| NCT06918808 | DB-3Q | Phase 2 | Perianal Fistula Due to Crohn's Disease | Immunology | Jul 2027 |
| NCT05354141 | ExoFlo | Phase 3 | Acute Respiratory Distress Syndrome | Respiratory | Nov 2027 |
No annotated target.
–
Genrix (Shanghai) Biopharmaceutical Mediar Therapeutics Bluefin Biomedicine Doron Therapeutics UnicoCell Biomed
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.